Locations
Branford, CT, USA · Farmington, CT, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Seed
founded in
2020
RIGImmune is a biopharmaceutical company founded in 2020 by prominent Yale University professors, focusing on developing innovative RNA therapeutics delivered directly to the respiratory tract without lipid nanoparticle systems. The company has created a unique technology platform called NEED™ (Nano-Emulsion Enhanced Delivery) for the effective delivery of RNA therapeutics, particularly targeting respiratory diseases with high unmet medical needs. RIGImmune's pipeline includes RIG 101 for asthma and RIG-301 CFTR for cystic fibrosis, showcasing its commitment to addressing serious respiratory conditions. The company has executed an exclusive license agreement with Yale University for intellectual property related to its innovative stem loop RNA therapeutics, positioning it strongly in the biopharmaceutical market.
Something looks off?